ArticleFrontiers in neuroscience2025
Loss of Nocturnin increases neuronal viability in oxidative stress conditions.
Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- NAD⁺ biology and supplementation: From mechanisms to clinical perspectives.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Oxidative stress, characterized by an imbalance between reactive oxygen species (ROS) and antioxidants, plays a critical role in neurodegenerative disorders like Parkinson's Disease (PD) and is strongly associated with neuronal cell death. Nocturnin was identified as a NADP(H) phosphatase and key regulator of oxidative stress. NADPH serves as a crucial co-factor for enzymes which regenerate antioxidants, and downregulation of its levels increases sensitivity to oxidative stress mediated neurodegeneration. In this study, we examined how the loss of Nocturnin impacts redox homeostasis and neuronal survival in Cath.a-differentiated (CAD) cells and dopaminergic neurodegeneration in a mutant alpha-synuclein overexpression PD mouse model (DA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.